KMT2A and acute lymphoblastic leukemia: According to the WHO classification of leukemic neoplasms, ALL patients are categorized into standard, low, intermediate, or high risk groups according to the identified molecular and/or cytogenetic markers (i.e., MLL-AF4 and BCR-ABL rearrangements) and response to treatment (21).